Pfizer/Pharmacia integration
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Senior VP-Strategic Planning & Business Development Tom Booth will lead Consumer Healthcare division's transition team in the Pharmacia integration. Teams are responsible for "day-to-day transition planning process," serving as "focal point for two-way communication between the divisions and corporate and between the divisions themselves," says 1Pfizer employee newsletter article filed with SEC. Pfizer, Pharmacia team leaders will meet for first time Aug. 13. "Transition process will be carried out using Pfizer's existing governance structure, which went through a significant overhaul following the W-L merger, with more decision-making authority and accountability being given to the businesses," Pfizer says. Companies expect deal to close by year-end (2"The Tan Sheet" July 22, 2002, p. 8)...
You may also be interested in...
Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy
Pfizer's acquisition of Pharmacia likely will draw antitrust regulatory scrutiny to one of the combined firm's smallest product lines - OTC motion sickness tablets
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.